Kidney Failure, AcuteNCT00117416
Mean Arterial Pressure (MAP) and Renal Perfusion: Evaluation of Critically Ill Patients With Normal Creatinine or Reduced Renal Function
A study of Kidney Failure, Acute, run by University Hospital, Ghent at 1 site in Belgium.
Trial summary
The purpose of this study is to evaluate the renal perfusion depending on the MAP. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Failure, Acute
- Type of treatment
- Surgery or procedure
- How many people
- 0 participants
- Where
- 1 siteBelgium
- Study dates
- Feb 2003to Feb 2003
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Over 18 years old
- Intensive care patient
- Treated with vasopressor
- Given informed consent
- Arterial infusion
- A bladder catheter
Who cannot join
- Anamneses of hypertension
- Neurological trauma
- Acute renal insufficiency other than prerenal or acute tubular necrosis etiology
- Hepatorenal syndrome
- Treated with diuretics
- Mechanical ventilation and unstable
Trial locations and contacts
1 site in 1 country.
About this study
Official title: MAP and Renal Perfusion: Evaluation of Critically Ill Patients With Normal Creatinine or Reduced Renal Function
The purpose of this study is to evaluate the renal perfusion depending on the MAP.
- Conditions
- Kidney Failure, Acute
- Being tested
- controlling the MAP
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
controlling the MAPProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
creatinine clearance after 4 hours
Secondary outcomes (3)
resistance index
diuresis
urinary indices of renal function
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2005 (estimated)
- Study startFeb 2003
- Primary completionFeb 2003
- Study completionFeb 2003
Why it stopped: No subjects recruited
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney Failure, AcuteStudies of the same condition, open and under way.
- More trials run by University Hospital, GhentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Ghent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eric Hoste, MD, PhD, Principal investigator, University Hospital, Ghent
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00117416
- Sponsor's protocol ID
- 2002/382
- Status last verified
- Jul 2021
- First submitted
- 30 Jun 2005
- Last updated
- 20 Dec 2022
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MAP and Renal Perfusion: Evaluation of Critically Ill Patients With Normal Creatinine or Reduced Renal Function
- ClinicalTrials.gov ID
- NCT00117416
- Acronym / sponsor ID
- 2002/382
- Conditions
- Kidney Failure, Acute
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: No subjects recruited
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University Hospital, GhentUniversity, hospital or other
- Study start
- Feb 2003
- Primary completion
- Feb 2003
- Study completion
- Feb 2003
- First posted
- 6 Jul 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the renal perfusion depending on the MAP.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Over 18 years old
- Intensive care patient
- Treated with vasopressor
- Given informed consent
- Arterial infusion
Key exclusion criteria (6 listed)
- Anamneses of hypertension
- Neurological trauma
- Acute renal insufficiency other than prerenal or acute tubular necrosis etiology
- Hepatorenal syndrome
- Treated with diuretics
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| controlling the MAP | Procedure or surgery | – |
Primary outcome
creatinine clearance after 4 hours
3 secondary outcomes
resistance index
diuresis
urinary indices of renal function
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2022.
- Website of the University Hospital GhentLink provided by the sponsor.
Related trials for Kidney Failure, Acute
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eric Hoste, MD, PhD principal investigator
University Hospital, Ghent
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Kidney Failure, Acute, run by University Hospital, Ghent at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 20 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
creatinine clearance after 4 hours. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2022; AzTrials last refreshed its copy on 8 Nov 2026.